O Shaughnessy Asset Management LLC Sells 10,485 Shares of Humana Inc. (NYSE:HUM)

O Shaughnessy Asset Management LLC decreased its holdings in shares of Humana Inc. (NYSE:HUM) by 56.1% during the first quarter, according to the company in its most recent disclosure with the SEC. The fund owned 8,204 shares of the insurance provider’s stock after selling 10,485 shares during the quarter. O Shaughnessy Asset Management LLC’s holdings in Humana were worth $2,845,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of the business. Rakuten Securities Inc. purchased a new stake in shares of Humana in the fourth quarter valued at approximately $25,000. Gradient Investments LLC boosted its holdings in shares of Humana by 200.0% in the fourth quarter. Gradient Investments LLC now owns 60 shares of the insurance provider’s stock valued at $27,000 after purchasing an additional 40 shares during the period. Cetera Trust Company N.A purchased a new stake in shares of Humana in the fourth quarter valued at approximately $28,000. Private Wealth Management Group LLC purchased a new stake in shares of Humana in the fourth quarter valued at approximately $32,000. Finally, Carolinas Wealth Consulting LLC lifted its holdings in Humana by 274.1% during the fourth quarter. Carolinas Wealth Consulting LLC now owns 101 shares of the insurance provider’s stock worth $46,000 after buying an additional 74 shares during the period. Institutional investors own 92.38% of the company’s stock.

Humana Price Performance

Humana stock traded up $0.43 during midday trading on Wednesday, reaching $386.30. The company had a trading volume of 860,030 shares, compared to its average volume of 1,746,547. The company has a market capitalization of $46.55 billion, a P/E ratio of 24.13, a P/E/G ratio of 2.23 and a beta of 0.51. Humana Inc. has a 12-month low of $298.61 and a 12-month high of $530.54. The firm’s fifty day simple moving average is $363.52 and its 200-day simple moving average is $347.00. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.67 and a quick ratio of 1.67.

Humana (NYSE:HUM) last issued its quarterly earnings results on Wednesday, April 24th. The insurance provider reported $7.23 earnings per share for the quarter, beating analysts’ consensus estimates of $6.12 by $1.11. Humana had a net margin of 1.82% and a return on equity of 17.76%. The firm had revenue of $29.61 billion for the quarter, compared to analyst estimates of $28.52 billion. During the same period last year, the company posted $9.38 EPS. Humana’s quarterly revenue was up 10.7% compared to the same quarter last year. As a group, equities analysts anticipate that Humana Inc. will post 16.27 EPS for the current year.

Analyst Ratings Changes

A number of analysts have weighed in on the company. Oppenheimer lowered their target price on Humana from $415.00 to $370.00 and set an “outperform” rating for the company in a report on Thursday, April 25th. Wells Fargo & Company lowered their target price on Humana from $413.00 to $350.00 and set an “overweight” rating for the company in a report on Monday, April 8th. Piper Sandler assumed coverage on Humana in a research report on Wednesday, June 26th. They set an “overweight” rating and a $392.00 price target on the stock. Cantor Fitzgerald reissued a “neutral” rating and issued a $360.00 target price on shares of Humana in a research report on Tuesday. Finally, Royal Bank of Canada cut their target price on Humana from $415.00 to $353.00 and set an “outperform” rating on the stock in a research report on Thursday, April 25th. Fourteen investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat, Humana presently has a consensus rating of “Hold” and a consensus price target of $402.60.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.